- Home
- GB vs ARQT Comparison
GB vs ARQT Comparison
Compare GB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GB
- ARQT
- Stock Information
- Founded
- GB 1980
- ARQT 2016
- Country
- GB Switzerland
- ARQT United States
- Employees
- GB N/A
- ARQT N/A
- Industry
- GB EDP Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- GB Technology
- ARQT Health Care
- Exchange
- GB Nasdaq
- ARQT Nasdaq
- Market Cap
- GB 1.5B
- ARQT 1.7B
- IPO Year
- GB N/A
- ARQT 2020
- Fundamental
- Price
- GB $7.40
- ARQT $14.29
- Analyst Decision
- GB Buy
- ARQT Strong Buy
- Analyst Count
- GB 1
- ARQT 7
- Target Price
- GB $6.00
- ARQT $18.67
- AVG Volume (30 Days)
- GB 31.8K
- ARQT 1.5M
- Earning Date
- GB 08-27-2025
- ARQT 08-06-2025
- Dividend Yield
- GB N/A
- ARQT N/A
- EPS Growth
- GB 483.33
- ARQT N/A
- EPS
- GB 0.38
- ARQT N/A
- Revenue
- GB $548,939,689.00
- ARQT $212,819,000.00
- Revenue This Year
- GB $15.17
- ARQT $61.83
- Revenue Next Year
- GB $6.50
- ARQT $36.55
- P/E Ratio
- GB $19.51
- ARQT N/A
- Revenue Growth
- GB 20.26
- ARQT 100.03
- 52 Week Low
- GB $4.29
- ARQT $7.86
- 52 Week High
- GB $8.00
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- GB 50.95
- ARQT 46.02
- Support Level
- GB $7.37
- ARQT $14.44
- Resistance Level
- GB $7.41
- ARQT $15.38
- Average True Range (ATR)
- GB 0.02
- ARQT 0.66
- MACD
- GB 0.01
- ARQT -0.09
- Stochastic Oscillator
- GB 74.03
- ARQT 10.19
About GB Global Blue Group Holding AG
Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.